Please login to the form below

Not currently logged in
Email:
Password:

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with moderate to severe rheumatoid arthritis in the US.

Latest news

More from news
Approximately 6 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics